المؤلفون: Lei Zheng, Jin-jing He, Kai-xiang Zhao, Ya-fei Pan, Wei-xian Liu

المصدر: Non-coding RNA Research, Vol 9, Iss 2, Pp 407-420 (2024)

مصطلحات موضوعية: Glioma, EMT, Tumor immune microenvironment, Prognosis, Individualized therapy, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2468054024000246Test; https://doaj.org/toc/2468-0540Test

الوصول الحر: https://doaj.org/article/4127a66423d04f718c3e87fbd676c9d9Test

المؤلفون: Dorit Fabricius, Tina Knieling, Noelle Zurmuehl, Leandra Makedon, Joachim Freihorst, Hanna Schmidt, Sebastian Bode

المصدر: Molecular and Cellular Pediatrics, Vol 11, Iss 1, Pp 1-11 (2024)

مصطلحات موضوعية: Cystic fibrosis, Vitamins, Trace elements, Micronutrients, Highly effective CFTR modulator therapy, Individualized therapy, Pediatrics, RJ1-570

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2194-7791Test

الوصول الحر: https://doaj.org/article/65b412cccdaf48c99e9aa37d8d881cccTest

المؤلفون: Jinmei Sun, Fengbo Xing, Jingjing Feng, Xin Chen, Lingling Lv, Xiaoqing Yao, Mengqi Wang, Ziye Zhao, Qian Zhou, Tingting Liu, Yuqian Zhan, Gong-Jun JI, Kai Wang, Panpan Hu

المصدر: Heliyon, Vol 10, Iss 12, Pp e32799- (2024)

مصطلحات موضوعية: Parkinson's disease, Repetitive transcranial magnetic stimulation, United Parkinson's disease rating scale part III, Motor symptom clusters, Baseline predictors, Individualized therapy, Science (General), Q1-390, Social sciences (General), H1-99

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2405844024088303Test; https://doaj.org/toc/2405-8440Test

الوصول الحر: https://doaj.org/article/ac0a962cf0c04ad9a81791000dfa87b1Test

المؤلفون: Xiaoqian Zhang, Jiale Zhang, Yan Ren, Ranran Sun, Xu Zhai

المصدر: Frontiers in Endocrinology, Vol 15 (2024)

مصطلحات موضوعية: diabetic nephropathy, panvascular disease, endothelial dysfunction, renin-angiotensin system, novel antidiabetic drugs, individualized therapy, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2024.1368481/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/ed84fafc5ab44375b1337026f2bdd500Test

المؤلفون: Miaomiao Gong, Han Meng, Dengxu Tan, Peng Li, Jing Qin, Qingling An, Changhong Shi, Jiaze An

المصدر: Animal Models and Experimental Medicine, Vol 6, Iss 5, Pp 409-418 (2023)

مصطلحات موضوعية: 3D culture, individualized therapy, organoid, pancreatic ductal adenocarcinoma, Medicine (General), R5-920

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2576-2095Test

الوصول الحر: https://doaj.org/article/a9cd2614a9c0469f92b64187e23273c3Test

المؤلفون: Yixin Shi, Zhanwen Guan, Gengxi Cai, Yichu Nie, Chuling Zhang, Wei Luo, Jia Liu

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: breast cancer, patient-derived organoids, tumor microenvironment, drug screening, individualized therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1350935/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/1e7dd405078d45a1aa74ad3e76f6b443Test

المؤلفون: Hang Sun, Lejia Sun, Xindi Ke, Lijuan Liu, Changcan Li, Bao Jin, Peipei Wang, Zhuoran Jiang, Hong Zhao, Zhiying Yang, Yongliang Sun, Jianmei Liu, Yan Wang, Minghao Sun, Mingchang Pang, Yinhan Wang, Bin Wu, Haitao Zhao, Xinting Sang, Baocai Xing, Huayu Yang, Pengyu Huang, Yilei Mao

المصدر: Advanced Science, Vol 11, Iss 2, Pp n/a-n/a (2024)

مصطلحات موضوعية: 3D bioprinting, cancer model, colorectal cancer, colorectal cancer liver metastases, individualized therapy, precision medicine, Science

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2198-3844Test

الوصول الحر: https://doaj.org/article/39ba9d67922d4b168aa7890aca74a9eeTest

المؤلفون: Yu Xiong, Yu-Meng Liu, Jia-Qiang Hu, Bao-Qiang Zhu, Yuan-Kui Wei, Yan Yang, Xing-Wei Wu, En-Wu Long

المصدر: Frontiers in Pharmacology, Vol 14 (2024)

مصطلحات موضوعية: type 2 diabetes mellitus, urinary tract infections, machine learning, predictive models, individualized therapy, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1259596/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/04d1374f41e84eca845e7717fbb67b15Test

المؤلفون: Zun-Qiang Zhou, Yi Zhang, Zi-Yang Xu, Xiao-Li Tang, Xiao-Hua Chen, Jiao Guan, Zheng-Yun Zhang

المصدر: Frontiers in Genetics, Vol 14 (2024)

مصطلحات موضوعية: cholangiocarcinoma, single-cell RNA sequencing, T cell, fibroblas, individualized therapy approach, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fgene.2023.1241834/fullTest; https://doaj.org/toc/1664-8021Test

الوصول الحر: https://doaj.org/article/ce9ed5f65fed4edbae71d09443e0330fTest

المؤلفون: N. N. Tsyba, A. G. Turkina, Н. Н. Цыба, А. Г. Туркина

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 89-100 ; Медицинский Совет; № 22 (2023); 89-100 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ремиссия без лечения, tyrosine kinase inhibitors, BCR::ABL tyrosine kinase, individualized therapy, therapy discontinuation, ингибиторы тирозинкиназ, BCR::ABL1-тирозинкиназа, отмена терапии, индивидуализация терапии

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7984/7071Test; Bennett JH. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburgh Med Surg J. 1845;(165):1–11. Available at: https://archive.org/details/b21470388Test.; Virchow R. Zur pathologischen Physiologie des Bluts. Archiv Pathol Anat. 1847;(1):547–563. https://doi.org/10.1007/BF02114475Test.; Minot GR, Buckman TE, Isaacs R. Chronic myelogenous leukemia: age incidence, duration, and benefit derived from irradiation. JAMA. 1924;82(19):1489–1494. https://doi.org/10.1001/jama.1924.02650450001001Test.; Senn N. The therapeutical value of the Rontgen ray in the treatment of pseudoleucaemia. New York Med J. 1903;77:665–668.; Shimkin MB, Mettier SR, Bierman HR. Myelocytic leukemia: an analysis of incidence, distribution and fatality, 1910–1948. Ann Intern Med. 1951;35(1):194–212. https://doi.org/10.7326/0003-4819-35-1-194Test.; Haddow A, Timmis GM. Myleran in chronic myeloid leukaemia chemical constitution and biological action. Lancet. 1953;264(6753):207–208. https://doi.org/10.1016/s0140-6736Test(53)90884-8.; Galton DA, Camb MB. Myleran in chronic myeloid leukaemia results of treatment. Lancet. 1953;264(6753):208–213. https://doi.org/10.1016/s0140-6736Test(53)90885-x.; Osgood EE. Treatment of chronic leukemias. J Nucl Med. 1964;5(2):139–153. Available at: https://jnm.snmjournals.org/content/5/2/139Test.; Haut A, Abbott WS, Wintrobe MM, Cartwright GE. Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy. Blood. 1961;17 (1):1–19. https://doi.org/10.1182/blood.V17.1.1.1Test.; Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–799. https://doi.org/10.1182/blood.V63.4.789.789Test.; Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol. 2011;29(29):3944–3945. https://doi.org/10.1200/JCO.2011.37.6962Test.; Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56. https://doi.org/10.1038/leu.2015.261Test.; Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82(2):398–407. https://doi.org/10.1182/blood.V82.2.398.398Test.; Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–267. https://doi.org/10.1098/rspb.1957.0048Test.; Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996;100(5):555–570. https://doi.org/10.1016/s0002-9343Test(96)00061-7.; Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–293. https://doi.org/10.1038/243290a0Test.; Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 1991;67(3):459–468. https://doi.org/10.1016/0092-8674Test(91)90521-y.; Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–1061. https://doi.org/10.1038/leu.2009.38Test.; Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007;249(2):121–132. https://doi.org/10.1016/j.canlet.2006.07.010Test.; Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374–7379. https://doi.org/10.1158/1078-0432.CCR-06-1516Test.; Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002;99(16):10700–10705. https://doi.org/10.1073/pnas.162140299Test.; Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276–283. https://doi.org/10.1182/blood-2002-09-2896Test.; Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168–2171. https://doi.org/10.1182/blood-2009-01-197186Test.; Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O’Brien S et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112(1):53–55. https://doi.org/10.1182/blood-2007-11-123950Test.; Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15(1):113. https://doi.org/10.1186/s13045-022-01334-zTest.; Lipton JH, Bryden P, Sidhu MK, Huang H, McGarry LJ, Lustgarten S et al. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res. 2015;39(1):58–64. https://doi.org/10.1016/j.leukres.2014.10.005Test.; Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917–927. https://doi.org/10.1056/NEJMoa1609324Test.; Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054. https://doi.org/10.1038/leu.2016.5Test.; Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333–2340. https://doi.org/10.1200/JCO.2015.64.8899Test.; Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377–386. https://doi.org/10.1002/cncr.24734Test.; Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27(1):107–112. https://doi.org/10.1038/leu.2012.181Test.; Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869–874. https://doi.org/10.1002/ajh.24423Test.; Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25):6322–6329. https://doi.org/10.1182/blood-2008-11-186817Test.; Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852–3861. https://doi.org/10.1002/cncr.25123Test.; Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014;89(7):732–742. https://doi.org/10.1002/ajh.23728Test.; Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016;91(12):1206–1214. https://doi.org/10.1002/ajh.24536Test.; Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231–237. https://doi.org/10.1200/JCO.2017.74.7162Test.; Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300–1310. https://doi.org/10.3109/10428194.2015.1091929Test.; Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137. https://doi.org/10.1161/CIRCULATIONAHA.111.079921Test.; Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261–263. https://doi.org/10.1182/blood-2008-09-180604Test.; Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75–е87. https://doi.org/10.1182/blood-2010-07-294330Test.; Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Spec Pharm. 2015;21(2):114–122. https://doi.org/10.18553/jmcp.2015.21.2.114Test.; Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26(29):4806–4813. https://doi.org/10.1200/JCO.2008.16.9953Test.; Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011;118(20):5697–5700. https://doi.org/10.1182/blood-2011-07-367326Test.; Molica M, Noguera NI, Trawinska MM, Martinelli G, Cerchione C, Abruzzese E. Treatment free remission in chronic myeloid leukemia: Lights and shadows. Hematol Rep. 2020;12(Suppl. 1):8950. https://doi.org/10.4081/hr.2020.8950Test.; Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20(1):214–220. https://doi.org/10.1200/JCO.2002.20.1.214Test.; Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109(1):58–60. https://doi.org/10.1182/blood-2006-03-011239Test.; Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035. https://doi.org/10.1016/S1470-2045Test(10)70233-3.; Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017;35(3):298–305. https://doi.org/10.1200/JCO.2016.68.2914Test.; Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–522. https://doi.org/10.1182/blood-2013-02-483750Test.; Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23. https://doi.org/10.1182/blood-2016-01-694265Test.; Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757. https://doi.org/10.1016/S1470-2045Test(18)30192-X.; Петрова АН, Челышева ЕЮ, Немченко ИС, Быкова АВ, Гурьянова МА, Кузьмина ЕА и др. Отдаленные результаты наблюдения больных хроническим миелолейкозом в ремиссии без лечения. Гематология и трансфузиология. 2023;68(1):21–34. https://doi.org/10.35754/0234-5730-2023-68-1-21-34Test.; Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717–723. https://doi.org/10.3324/haematol.2015.139899Test.; Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910–914. https://doi.org/10.1002/ajh.24120Test.; Breccia M. Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached. eClinicalMedicine. 2020;19:100277. https://doi.org/10.1016/j.eclinm.2020.100277Test.; Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENEST freedom study. Leukemia. 2017;31(7):1525–1531. https://doi.org/10.1038/leu.2017.63Test.; Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018;168(7):461–470. https://doi.org/10.7326/M17-1094Test.; Туркина АГ, Челышева ЕЮ, Шуваев ВА, Гусарова ГА, Быкова АВ, Шухов ОА и др. Результаты наблюдения больных хроническим миелолейкозом с глубоким молекулярным ответом без терапии ингибиторами тирозинкиназ. Терапевтический архив. 2017;89(12):86–96. https://doi.org/10.17116/terarkh2017891286-96Test.; Petrova A, Chelysheva E, Shukhov O, Bykova A, Nemchenko I, Gusarova G et al. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI. Clin Lymphoma Myeloma Leuk. 2020;20(5):267–271. https://doi.org/10.1016/j.clml.2019.12.019Test.; Туркина АГ, Челышева ЕЮ. Стратегия терапии хронического миелолейкоза: возможности и перспективы. Терапевтический архив. 2013;85(7): 4–9. Режим доступа: https://ter-arkhiv.ru/0040-3660/article/view/31271Test.; Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119(14):2620–2629. https://doi.org/10.1002/cncr.28106Test.; Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851–2857. https://doi.org/10.1200/JCO.2015.66.2866Test.; Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–2406. https://doi.org/10.1038/leu.2017.253Test.; Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104(8):1589–1596. https://doi.org/10.3324/haematol.2018.205054Test.; Maas CCHM, van Klaveren D, Ector GICG, Posthuma EFM, Visser O, Westerweel PE et al. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018. Br J Haematol. 2022;196(5):1219–1224. https://doi.org/10.1111/bjh.17989Test.; Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. https://doi.org/10.1038/s41375-020-01111-2Test.; Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138–2149. https://doi.org/10.1038/s41375-020-0931-9Test.; Shahrin NH, Wadham C, Branford S. Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication. Curr Hematol Malig Rep. 2022;17(6):171–180. https://doi.org/10.1007/s11899-022-00668-2Test.; Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126(1):67–75. https://doi.org/10.1002/cncr.32504Test.; Shukhov O, Vinogradova O, Chelysheva E, Bykova A, Nemchenko I, Lazareva O, Turkina A. PB1970: Long-Term Results of Therapy for Chronic Myeloid Leukemia: A 20-Year Analysis of the GIPAP PROGRAM in Russia. Hemasphere. 2023;7(Suppl.):e3705261. https://doi.org/10.1097/01.HS9.0000974696.37052.61Test.; Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–1987. https://doi.org/10.1182/blood-2011-08-358135Test.; Patel AB, O’Hare T, Deininger MW. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589–612. https://doi.org/10.1016/j.hoc.2017.04.007Test.; Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94(1):46–54. https://doi.org/10.1002/ajh.25306Test.; Henk HJ, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37(1):124–133. https://doi.org/10.1016/j.clinthera.2014.10.019Test.; Copland M. Is There a Role for Dose Modification of TKI Therapy in CML? Curr Hematol Malig Rep. 2019;14(4):337–345. https://doi.org/10.1007/s11899-019-00524-wTest.; Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042–2050. https://doi.org/10.1182/blood.2021012082Test.; Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020;4(3):530–538. https://doi.org/10.1182/bloodadvances.2019000268Test.; Jabbour EJ, Deininger MW, Abruzzese E, Apperley JF, Cortes JE, Chuah C et al. Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. Blood. 2021;138(Suppl. 1):2550. https://doi.org/10.1182/blood-2021-146175Test.; Pasvolsky O, Leader A, Iakobishvili Z, Wasserstrum Y, Kornowski R, Raanani P. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardiooncology. 2015;1(1):5. https://doi.org/10.1186/s40959-015-0008-5Test.; Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136(22):2507–2512. https://doi.org/10.1182/blood.2020006911Test.; Chen Y, Liu Z, Zou J, Wang D, He W, Meng L et al. Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China. Haematologica. 2022;107(8):1966–1970. https://doi.org/10.3324/haematol.2022.280637Test.; Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193(2):346–355. https://doi.org/10.1111/bjh.17286Test.; Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375–e383. https://doi.org/10.1016/S2352-3026Test(19)30094-8.; Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C. Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer. 2021;21(1):60. https://doi.org/10.1186/s12885-021-07782-zTest.; Saglio G, Fava C, Gale RP. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? Haematologica. 2019;104(5):862–864. https://doi.org/10.3324/haematol.2018.214445Test.; Iurlo A, Cattaneo D, Bucelli C, Breccia M. Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. J Clin Med. 2021;10(3):515. https://doi.org/10.3390/jcm10030515Test.; Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J et al. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022;97(11):1419–1426. https://doi.org/10.1002/ajh.26686Test.; Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97(11):1413–1418. https://doi.org/10.1002/ajh.26689Test.; Kota V, Brümmendorf TH, Gambacorti-Passerini C, Lipton JH, Kim DW, An F et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. Leuk Res. 2021;111:106690. https://doi.org/10.1016/j.leukres.2021.106690Test.; Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11(1):143. https://doi.org/10.1186/s13045-018-0685-2Test.; Rea D, Cayuela JM, Dulucq S, Etienne G. Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED). Blood. 2017;130(Suppl. 1):318. https://doi.org/10.1182/blood.V130.Suppl_1.318.318Test.; Stagno F, Abruzzese E, Iurlo A, Pane F, Attolico I, Sportoletti P et al. Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study. Blood. 2022;140(Suppl. 1):9614–9616. https://doi.org/10.1182/blood-2022-157700Test.; Шухов ОА, Гурьянова МА, Челышева ЕЮ, Быкова АВ, Петрова АН, Немченко ИС и др. Оценка стабильности молекулярного ответа у больных хроническим миелоидным лейкозом на сниженных дозах ингибиторов тирозинкиназ второго поколения. Гематология и трансфузиология. 2020;65(1):111–112. Режим доступа: https://www.htjournal.ru/jour/article/view/195/163Test.; Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. https://doi.org/10.1038/s41375-020-0776-2Test.; Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(10):1385–1415. https://doi.org/10.6004/jnccn.2020.0047Test.; Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232–238. https://doi.org/10.1200/JCO.2011.38.6565Test.; Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353–1360. https://doi.org/10.1182/blood-2013-06-510396Test.; Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013;98(11):1686–1688. https://doi.org/10.3324/haematol.2013.090282Test.; Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematology Am Soc Hematol Educ Program. 2018;(1):168–176. https://doi.org/10.1182/asheducation-2018.1.168Test.; Kantarjian HM, O’Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97(4):1033–1041. https://doi.org/10.1002/cncr.11223Test.; Shaya J, Pettit K, Kandarpa M, Bixby D, Mercer J, Talpaz M. Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk. 2022;22(1):17–23. https://doi.org/10.1016/j.clml.2021.07.001Test.; Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023;98(4):639–644. https://doi.org/10.1002/ajh.26836Test.; Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34(6):1495–1502. https://doi.org/10.1038/s41375-020-0842-9Test.; Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer J. 2023;13(1):58. https://doi.org/10.1038Test/ s41408-023-00823-9.; Craddock CF. We do still transplant CML, don’t we? Hematology Am Soc Hematol Educ Program. 2018;(1):177–184. https://doi.org/10.1182/asheducation-2018.1.177Test.; Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J et al. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol. 2023;98(1):112–121. https://doi.org/10.1002/ajh.26764Test.; Radich J. Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet! Am J Hematol. 2023;98(1):4–5. https://doi.org/10.1002/ajh.26790Test.; Kantarjian HM, O’Brien SM, Keating M, Beran M, Estey E, Giralt S et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11(10):1617–1620. https://doi.org/10.1038/sj.leu.2400796Test.; Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015;121(10):1637–1644. https://doi.org/10.1002/cncr.29240Test.; Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S et al. Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des. 2007;70(3):171–181. https://doi.org/10.1111/j.1747-0285.2007.00556.xTest.; O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412. https://doi.org/10.1016/j.ccr.2009.09.028Test.; Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–1796. https://doi.org/10.1056/NEJMoa1306494Test.; Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404. https://doi.org/10.1182/blood-2016-09-739086Test.; Breccia M, Olimpieri PP, Celant S, Olimpieri O, Pane F, Iurlo A et al. Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA). Br J Haematol. 2022;198(6):965–973. https://doi.org/10.1111/bjh.18359Test.; Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023;98(4):658–665. https://doi.org/10.1002/ajh.26852Test.; Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–2041. https://doi.org/10.1182/blood.2020009984Test.; Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617–626. https://doi.org/10.1038/s41375-023-01829-9Test.; Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37(5):1048–1059. https://doi.org/10.1038/s41375-023-01860-wTest.; Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019;381(24):2315–2326. https://doi.org/10.1056/NEJMoa1902328Test.; Туркина АГ, Кузьмина ЕА, Ломаиа ЕГ, Морозова ЕВ, Челышева ЕЮ, Шухов ОА и др. Асциминиб у больных хроническим миелолейкозом, не имеющих альтернативных методов лечения: результаты исследования в рамках программы расширенного доступа МАР (Managed Access Program, NCT04360005) в России. Клиническая онкогематология. 2023;16(1):54–68. Режим доступа: https://bloodjournal.ru/wp-content/uploads/2022/12/6.pdfTest.; Chee LCY, Lee N, Grigg A, Chen M, Schwarer A, Szer J et al. Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia. Blood. 2022;140(Suppl. 1):6800–6802. https://doi.org/10.1182/blood-2022-163221Test.; Khadadah F, Xenocostas A, Busque L, Jamani K, Cerquozzi S, Kuruvilla P et al. A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy. Blood. 2021;138(Suppl. 1):3610. https://doi.org/10.1182/blood-2021-149588Test.; Breccia M, Russo RAV, Martino B, Abruzzese E, Annunziata M, Binotto G et al. P712: Asciminib Italian managed access program: efficacy profile in heavily pre-treated cml patients. HemaSphere. 2022;(6):607–608. https://doi.org/10.1097/01.HS9.0000845732.28959.a9Test.; Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol. 2022;101(10):2263–2270. https://doi.org/10.1007/s00277-022-04932-6Test.; Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F et al. Real-World Experience of Asciminib: Factors Associated with Response. Blood. 2022;140(Suppl. 1):6796–6797. https://doi.org/10.1182/blood-2022-165501Test.; Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK et al. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023;149(9):6247–6262. https://doi.org/10.1007/s00432-022-04562-5Test.; https://www.med-sovet.pro/jour/article/view/7984Test

الإتاحة: https://doi.org/10.21518/ms2023-362Test
https://doi.org/10.1007/BF02114475Test
https://doi.org/10.1001/jama.1924.02650450001001Test
https://doi.org/10.7326/0003-4819-35-1-194Test
https://doi.org/10.1016/s0140-6736Test(53)90884-8
https://doi.org/10.1016/s0140-6736Test(53)90885-x
https://doi.org/10.1182/blood.V17.1.1.1Test
https://doi.org/10.1182/blood.V63.4.789.789Test
https://doi.org/10.1200/JCO.2011.37.6962Test
https://doi.org/10.1038/leu.2015.261Test